Bobak R. Azamian
CEO, President at Tarsus Pharmaceuticals, Inc. (TARS)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $5.2M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 9SEC | TARSTarsus Pharmaceuticals, Inc. | Sell Plan | 7,100830,891 held (−1%) | $90.27 | $641K | -19.0% |
| Sep 9SEC | TARSTarsus Pharmaceuticals, Inc. | Sell Plan | 2,900827,991 held (−0%) | $91.27 | $265K | -19.8% |
| Sep 3SEC | TARSTarsus Pharmaceuticals, Inc. | Sell Plan | 10,000837,991 held (−1%) | $80.06 | $801K | -8.6% |
| Jun 22SEC | TARSTarsus Pharmaceuticals, Inc. | Sell Plan | 4,582853,409 held (−1%) | $61.24 | $281K | +19.5% |
| Jun 22SEC | TARSTarsus Pharmaceuticals, Inc. | Sell Plan | 5,418847,991 held (−1%) | $61.81 | $335K | +18.4% |
| Mar 19SEC | TARSTarsus Pharmaceuticals, Inc. | Sell | 10,97257,052 held (−16%) | $69.42 | $762K | +5.4% |
| Mar 19SEC | TARSTarsus Pharmaceuticals, Inc. | Sell | 11,66745,385 held (−20%) | $68.71 | $802K | +6.5% |
| Mar 19SEC | TARSTarsus Pharmaceuticals, Inc. | Sell | 11,96433,421 held (−26%) | $67.00 | $802K | +9.2% |
| Dec 30SEC | TARSTarsus Pharmaceuticals, Inc. | Sell Plan | 5,443858,548 held (−1%) | $82.41 | $449K | -11.2% |
| Dec 30SEC | TARSTarsus Pharmaceuticals, Inc. | Sell Plan | 557857,991 held (−0%) | $83.54 | $47K | -12.4% |
- Sell
CEO, President Bobak R. Azamian sold $641K of TARS at $90.27 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Bobak R. Azamian sold $265K of TARS at $91.27 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Bobak R. Azamian sold $801K of TARS at $80.06 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Bobak R. Azamian sold $281K of TARS at $61.24 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Bobak R. Azamian sold $335K of TARS at $61.81 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Bobak R. Azamian sold $802K of TARS at $67.00 — cuts the stake by 26%.